Indication
As monotherapy for the treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive (IHC3+) biliary tract cancer (BTC) previously treated with at least 1 prior line of systemic therapy.
Medicine details
- Medicine name:
- zanidatamab (Ziihera)
- SMC ID:
- SMC2938
- Pharmaceutical company
- Jazz Pharmaceuticals
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC